Fig. 2

SRSF9 promotes proliferation, migration and invasion by CRC cells in vitro and tumor growth in vivo. A, B The indicated stable cells were subjected to qRT-PCR (left) and Western blotting (right) (*P < 0.05, Student’s t test). C, D CCK-8 and colony formation assays were performed in SRSF9-expressing CRC cells (*p < 0.05; **p < 0.01; ***p < 0.001, two-way ANOVA and Student’s t test). E Cell cycle distribution was analyzed by flow cytometry in SRSF9-expressing CRC cells (*p < 0.05; ***p < 0.001, one-way ANOVA). F, G Transwell assays were employed in SRSF9-expressing CRC cells. Scale bar = 100 μm. (*p < 0.05; **p < 0.01; NS: not significant, Student’s t test). H, I Wound healing assays were performed in SRSF9-expressing CRC cells. Scale bar = 200 μm (*p < 0.05; ***p < 0.001, Student’s t test). J The indicated stable cells were subjected to Western blotting. K Tumor nodules were collected and used to evaluate the difference in growth that occurred due to the influence of SRSF9. L Tumor growth curve based on tumor size measurements (****p < 0.0001, two-way ANOVA). Data are presented as the mean ± standard deviation of the values obtained in three independent experiments